Discovery and Characterization of a Selective Inhibitor of Synaptojanin1 5-Phosphatase Activity
ACS Pharmacology & Translational Science · 12.09.2025 · 8 (9) · 2996-3006
DOI: 10.1021/acsptsci.5c00210 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Pharmacology & Translational Science, online erschienen am 12.05.2025. Verfasst von Ella Martin und 10 weiteren Autor:innen. Beteiligte Einrichtung: VIB-VUB Center for Structural Biology, VIB, Brussels 1050, Belgium. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Vrije Universiteit Brussel, Fonds Wetenschappelijk Onderzoek.
Abstract (Originalsprache)
Synaptojanin1 is a presynaptic phosphoinositide phosphatase that harbors two catalytic domains: an N-terminal suppressor of actin 1-like (Sac1) domain that predominantly dephosphorylates PI(3)P and PI(4)-P and a central 5-phosphatase (5-PPase) domain that dephosphorylates PI-(4,5)-P2 and PI-(3,4,5)-P3. While loss-of-function mutations in Synaptojanin1 are associated with epilepsy and Parkinson's disease, inhibition of the 5-phosphatase activity of Synaptojanin1 was identified as a potential therapeutic approach for Alzheimer's disease, Down syndrome, and TBC1D24-associated epilepsy. However, the high conservation of active site residues among the different human 5-phosphatases has hampered the identification of Synaptojanin1-selective inhibitors. Here, we identified epigallocatechin monogallate and gambogic acid as inhibitors of the Synaptojanin1 5-phosphatase activity via a combination of high-throughput screening and structure-based virtual screening. While epigallocatechin monogallate shows promiscuous inhibition of all tested human 5-phosphatase, gambogic acid is selective for Synatojanin1. Correspondingly, kinetic analysis demonstrates that gambogic acid acts as a potent (K i = 0.51 μM) noncompetitive Synaptojanin1 inhibitor, suggesting that it targets a less conserved allosteric pocket rather than the active site. Together, these findings propose gambogic acid as a promising lead compound for the development of new selective inhibitors of Synaptojanin1.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- VIB-VUB Center for Structural Biology, VIB, Brussels 1050, Belgium.
- Structural Biology Brussels, Vrije Universiteit Brussel, Brussels 1050, Belgium.
- Research Group of Organic Chemistry, Vrije Universiteit Brussel, Brussels 1050, Belgium.
- VIB Screening Core, Ghent 9052, Belgium.
- VIB Protein Core, Ghent 9052, Belgium.
- VIB-KU Leuven Center for Brain and Disease Research, Leuven 3000, Belgium.
ORCID-Profile: Ella Martin, Danaë Giakoumakis, Christian Galicia, Steven Ballet, Wim Versées
Förderung
- Vrije Universiteit Brussel
- Fonds Wetenschappelijk Onderzoek
Zitieren
APA
Martin, E., Giakoumakis, D., Paesmans, J., Bisi, N., Drozdzecki, A., Audenaert, D., Haustraete, J., Verstreken, P., Galicia, C., Ballet, S., & Versées, W. (2025). Discovery and Characterization of a Selective Inhibitor of Synaptojanin1 5-Phosphatase Activity. ACS Pharmacology & Translational Science, 8(9), 2996-3006. https://doi.org/10.1021/acsptsci.5c00210
Vancouver
Martin E, Giakoumakis D, Paesmans J, Bisi N, Drozdzecki A, Audenaert D, et al. Discovery and Characterization of a Selective Inhibitor of Synaptojanin1 5-Phosphatase Activity. ACS Pharmacology & Translational Science. 2025;8(9):2996-3006. doi:10.1021/acsptsci.5c00210
BibTeX
@article{Martin2025,
author = {Martin, Ella and Giakoumakis, Danaë and Paesmans, Jone and Bisi, Nicolò and Drozdzecki, Andrzej and Audenaert, Dominique and Haustraete, Jurgen and Verstreken, Patrik and Galicia, Christian and Ballet, Steven and Versées, Wim},
title = {Discovery and Characterization of a Selective Inhibitor of Synaptojanin1 5-Phosphatase Activity},
journal = {ACS Pharmacology & Translational Science},
year = {2025},
volume = {8},
number = {9},
pages = {2996--3006},
doi = {10.1021/acsptsci.5c00210}
}
EUVIMED